Cue Biopharma, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-153.1M | $-5.2M | $1.6M | $-7.4M | $-8.5M | $-12.3M | $-9.5M | $-8.7M |
| Depreciation & Amortization | $36.0K | $566.0K | $678.0K | $80.0K | $99.0K | $101.0K | $98.0K | $101.0K |
| Depreciation | $33.0K | $74.0K | $66.0K | $76.0K | $97.0K | $97.0K | $92.0K | $97.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $23.8M | $48.0K | $610.0K | $1.5M | $1.3M | $1.3M | $1.6M | $1.6M |
| Net Cash from Operating Activities | $-29.0M | $-10.9M | $-1.1M | $-9.0M | $-3.4M | $-8.2M | $-9.0M | $-7.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $121.0K | $0 | $0 | $27.0K | $150.0K | $2.0K | $-1.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $0 | $-121.0K | $7.0M | $-6.8M | $-27.0K | $-150.0K | $-1.0K | $98.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $30.0M | $306.0K | $9.5M | $1.0K | $17.8M | $-1.0M | $-932.0K | $9.8M |
| Net Change in Cash | $1.0M | $-10.8M | $15.4M | $-15.8M | $14.4M | $-9.3M | $-10.0M | $2.4M |
| Free Cash Flow | $-29.0M | $-11.1M | $-1.1M | $-9.0M | $-3.4M | $-8.3M | $-9.0M | $-7.5M |